Technical Roundup on Research Services Stocks -- Myriad Genetics, QIAGEN, INC Research, and Bioanalytical Systems

Thursday, April 27, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 27, 2017 /PRNewswire/ --

The Research Services space comprises companies that offer services such

as aiding in marketing activities, and studying and analyzing the market as per client needs and specifications. Pre-market, observes the recent performances of these four stocks: Myriad Genetics Inc. (NASDAQ: MYGN), QIAGEN N.V. (NASDAQ:
QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Bioanalytical Systems Inc. (NASDAQ: BASI). Sign up today and download for free the research reports for the stocks covered today at:

Myriad Genetics

Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock finished Wednesday's session 0.71% higher at $18.46 with a total trading volume of 1.11 million shares. The Company's shares have advanced 14.02% in the previous three months and 10.74% since the start of this year. The stock is trading 1.29% below its 50-day moving average. Additionally, shares of Myriad Genetics, which focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide, have a Relative Strength Index (RSI) of 50.00.

On April 18th, 2017, Myriad Genetics announced that the Company will hold its Q3 FY17 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 02nd, 2017. During the call, Mark C. Capone, President and CEO, and Bryan Riggsbee, CFO, will provide an overview of the Company's financial performance for reported quarter and provide a business update. MYGN complete research report is just a click away at:


On Wednesday, shares in Venlo, the Netherlands headquartered QIAGEN N.V. recorded a trading volume of 1.41 million shares, which was above their three months average volume of 784,280 shares. The stock ended the session 0.98% higher at $29.91. The Company's shares have advanced 3.14% in the last one month, 7.55% in the previous three months, and 6.76% on an YTD basis. The stock is trading 3.64% above its 50-day moving average and 9.45% above its 200-day moving average. Moreover, shares of QIAGEN, which provides sample to insight solutions that transform biological materials into valuable molecular insights worldwide, have an RSI of 71.16.

On April 12th, 2017, QIAGEN announced that two peer-reviewed studies indicated the potential additional clinical value for QuantiFERON-TB® Gold Plus (QFT-Plus®), the fourth-generation test using enhanced QuantiFERON technology to detect latent tuberculosis infection. The studies conducted at the Stanford University School of Medicine and Japan's National Hospital Organization Hokkaido Medical Center focused on potential benefits of novel CD8+ T-cell stimulating antigens contained in QFT-Plus®. The complimentary report on QGEN can be downloaded at:

INC Research

Raleigh, North Carolina headquartered INC Research Holdings Inc.'s shares closed the day 1.02% lower at $43.85. The stock recorded a trading volume of 1.23 million shares, which was higher than its three months average volume of 981,340 shares. The Company's shares have gained 0.92% in the last month. The stock is trading 5.73% below its 50-day moving average. Additionally, shares of INC Research, which provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, Middle East and Africa, Asia/Pacific, and Latin America, have an RSI of 38.20.

On April 25th, 2017, INC Research and IAOCR, the accrediting organization for the international clinical research industry, announced that INC Research has achieved the "Silver Standard" within the IAOCR Clinical Operations Workforce Quality Accreditation program. INC Research is the first contract research organization ("CRO") to achieve the Silver Accreditation. This accomplishment follows the Company's achievement in 2016 as the first CRO to achieve IAOCR's bronze-level designation. Sign up for your complimentary report on INCR at:

Bioanalytical Systems

Shares in West Lafayette, Indiana headquartered Bioanalytical Systems Inc. finished 1.61% lower at $1.22. The stock recorded a trading volume of 28,581 shares. The Company's shares have advanced 46.99% in the previous three months and 58.44% on an YTD basis. The stock is trading above its 200-day moving average by 14.28%. Furthermore, shares of Bioanalytical Systems, which provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the US, other North America, Pacific Rim, Europe, and internationally, have an RSI of 43.43. Download the research report for free on BASI at:


Stock Callers:

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store